300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Construction
Oil and Gas
Film
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Japan
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
HealthCare Ventures, VC Fund

HealthCare Ventures

VC Fund

Cambridge, United States

HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.

Total investments:
104
Last investment:
Lead investor:
17%
Fund size:
$250M
Last fund:

Last updated:

Industries HealthCare Ventures invests in

BiotechnologyHealth CarePharmaceuticalMedicalTherapeutics

Stages HealthCare Ventures invests in

Series BSeries ASeries CFunding RoundSeries D

Countries HealthCare Ventures invests in

United StatesAustraliaUnited Kingdom

Round sizes

Series A $4.4M–$37MSeries B $10M–$50MSeries C $15M–$44M

Contacts

NameEmailPhoneSocials
See all 7 contacts →

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$4.4M–$37M
Series B
$10M–$50M
Series C
$15M–$44M

Investment Focus

Industry

  • Biotechnology 48 (46%)
  • Health Care 35 (34%)
  • Pharmaceutical 22 (21%)
  • Medical 21 (20%)
  • Therapeutics 14 (13%)
See all 34 industries →

Stage

  • Series B 27 (26%)
  • Series A 22 (21%)
  • Series C 11 (11%)
  • Funding Round 9 (9%)
  • Series D 7 (7%)
See all 12 stages →

Country

  • United States 53 (51%)
  • Australia 1 (1%)
  • United Kingdom 1 (1%)

Team

NameTitleInvestmentsLinksEmail
James H. Cavanaugh
James H. Cavanaugh Managing Director
Managing Director Total investments: 4 Find email
John Littlechild Managing Director & General Partner
Managing Director & General Partner Total investments: 0
Find email
Christopher K. Mirabelli Managing Director
Managing Director Total investments: 11
Find email
Douglas E. Onsi
Douglas E. Onsi Managing Director
Managing Director Total investments: 1
Find email
Harold Werner
Harold Werner Co-Founder & Managing Director
Co-Founder & Managing Director Total investments: 5
Find email
See all 7 team members →

Investments

CompanyDescriptionRoundLinks
Colorescience is a luxury aesthetic makeup line in the medical and resort spa channel, differentiating their products from other makeup lines through high quality, efficacious ingredients, luxury colores and formulations, and convenience and simplicity of use. With every product the company strives to make a difference in the diminution of skincancer and skin conditions. $30M / Debt Financing / Sep 14, 2020
Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology. Jan 01, 2016
Cypherpunk Technologies is a biopharmaceutical company developing antibody therapies for cancer while simultaneously executing a digital-asset treasury strategy centered on Zcash. Their oncology pipeline includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK-1, and FL-501, another antibody in preclinical development. Venture - Series Unknown / Jan 01, 2016
Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease. $37M / Series B / Sep 08, 2015
Galleon Pharmaceuticals engages in the discovery and development of medicines for breathing-control conditions in the United States. It focuses on developing a portfolio of therapeutics for the treatment of sleep apnea, ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, obesity-hypoventilation syndrome, and othercommon diseases. The company was incorporated in 2003 and is based in Horsham, Pennsylvania. $10M / Series B / Jun 11, 2015
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. $25M / Series B / Feb 10, 2015
Colorescience is a luxury aesthetic makeup line in the medical and resort spa channel, differentiating their products from other makeup lines through high quality, efficacious ingredients, luxury colores and formulations, and convenience and simplicity of use. With every product the company strives to make a difference in the diminution of skincancer and skin conditions. $15M / Series B / Sep 10, 2014
Senseonics is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that is intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring("CGM") system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life. $20M / Jun 05, 2014
PathoGenetiX is developing an automated system for the rapid identification of pathogenic bacterial strains using proprietary Genome Sequence Scanning Technology. The company's approach, which employs a single reagent set to generate genomic bar codes based on bacterial DNA, can cost-effectively identify thousands of strains in a single testfrom complex samples in three hours. PathoGenetiX is developing its GSS platform for use in genomics research, food and product safety testing, and clinical infectious disease diagnostics, with the initial commercial introduction into the research market planned for 2012. Series C / Oct 30, 2013
Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for thetreatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California. Post-IPO Equity / Apr 01, 2013
See all 104 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Construction
Oil and Gas
Film
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Japan
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does HealthCare Ventures invest in?

HealthCare Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 104 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is HealthCare Ventures's check size?

HealthCare Ventures typically joins rounds of $4.4M–$37M at Series A, $10M–$50M at Series B and $15M–$44M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HealthCare Ventures participates in.

How do I contact HealthCare Ventures?

Public channels for HealthCare Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at HealthCare Ventures?

The team at HealthCare Ventures includes James H. Cavanaugh (Managing Director), John Littlechild (Managing Director & General Partner) and Christopher K. Mirabelli (Managing Director), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
HealthCare Ventures HealthCare Ventures Find emails